Biofrontera Inc - Warrants (27/10/2026)
BFRIW
Get informed when a big investor buys or sells
+ FollowMarket Cap$77.54K
Close$
$-0.25
4341.7% downside
Current Fair Value
4341.7% downsideOvervalued by 4341.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $77,542.00 |
|---|---|
| Enterprise Value | $2.92 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.04 |
| Beta | 0.8 |
| Outstanding Shares | 12,923,710 |
Return
| Return on Equity | -106.87% |
|---|---|
| Return on Assets | -26.45% |
| Return on Invested Capital | -50.93% |
Valuation & Multiples
| P/E Ratio | -1.62 |
|---|---|
| PEG | 1.82 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.06 |
| Enterprise Value to EBIT | -0.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.57 |
| Debt to Equity | 1.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$9.50 M
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$8.25 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biofrontera Inc
82 employees
CEO: Hermann Lübbert Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company off...